Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat Mesylate in COVID-19 Pneumonia
NCT04418128Phase 3Unknown
- Sponsor
- Gyeongsang National University Hospital
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of Nafabelltan in COVID-19 pneumonia (2 arms), sponsored by Gyeongsang National University Hospital. Primary endpoint: Proportion of patients with clinical improvement at Day 28. Status: unknown.
02
Drugs
Nafabelltan
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04418128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418128.